Liminatus Pharma, Inc Class A Common Stock
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | |||
EBITDA | -1,100 | -8,149 | -1,803 |
EBIT | -8,149 | -1,804 | |
Net Income | -1,123 | -8,168 | -1,823 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -2,015 | -386 | -613 |
Cash | 1,907 | 337 | 724 |
Basic Shares | 23,753 | 23,753 | 27,007 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -9,988 | -2,747 | -1,089 | -2,709 |
EBIT | -9,990 | |||
Net Income | -10,206 | -2,904 | -1,226 | -2,928 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -9,976 | -3,106 | -3,345 | -869 |
Cash | 337 | 804 | 434 | 5,048 |
Basic Shares | 23,753 | 7,191 | 8,012 | 34,428 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.03 |
2025-12-31 | -$0.30 |
2025-09-30 | -$0.07 |
2025-06-30 | $0.004 |